Improved survival and health care use with CAR-T vs historical care in relapsed/refractory large B-cell lymphoma
Open Access
- 30 March 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (7) , 2304-2313
Abstract
Anti-CD19 chimeric antigen receptor T-cell (CAR-T) immunotherapies have been funded in Canada for relapsed/refractory large B-cell lymphoma (R/R-LBCL) after 2 lines of systemic therapy since late 2019. Real-world outcome data have been limited by lack of comparison to historical care. Using propensity-weighted analysis, we compared 3-year survival, health care resource use (HRU), and hospitalization events for patients with R/R-LBCL treated with CAR-T (n = 85) vs historical controls (HCs) treated before CAR-T approval who would have been eligible based on present criteria (n = 150). CAR-T 3-year overall survival (OS) was 59% (95% confidence interval [CI], 42-72; median, not reached) vs 10% (95% CI, 5-16; median, 4.4 months) in HCs. Three-year CAR-T progression-free survival (PFS) was 48% (95% CI, 32-63]; median, 14.4 months) vs 6% (95% CI, 3-11; median, 3.6 months) in HCs. The hazard ratio (HR) for OS was 0.21 (95% CI, 0.14-0.31), and for PFS was 0.28 (95% CI, 0.2-0.39), comparing CAR-T vs HCs. Per 1000 person-days at risk, patients receiving CAR-T had fewer hospital admissions than HCs (5.32 vs 9.1), emergency visits (2.33 vs 4.81), and intensive care admissions (0.53 vs 1.25), plus lower hospitalization rates for fever (0.93 vs 1.63), infection (1.48 vs 3.08), and neutropenia (0.66 vs 1.97; all P< .001). CAR-T produced a sustained survival benefit, and, despite well-described CAR-T toxicities, HCs experienced more hospitalization events, underscoring the lack of effective salvage treatments. As one of the largest real-world comparisons of patients with R/R-LBCL receiving CAR-T vs previous standard of care, this study demonstrated its improved effectiveness and reduced HRU.Keywords
This publication has 32 references indexed in Scilit:
- Bridging gaps in clinical trial accessibility and reimbursement for large B‐cell lymphoma therapies across EuropeHemaSphere, 2025
- 423P Marginalization and factors associated with early mortality among patients diagnosed with de novo metastatic breast cancer in Ontario, CanadaAnnals of Oncology, 2024
- Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphomaLeukemia & Lymphoma, 2024
- End-of-Life Care for Older Adults with Aggressive Non-Hodgkin LymphomaJournal of Palliative Medicine, 2022
- Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 studyThe Lancet Oncology, 2021
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaNew England Journal of Medicine, 2019
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialThe Lancet Oncology, 2019
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL studyBone Marrow Transplantation, 2015
- Variable Selection for Propensity Score ModelsAmerican Journal of Epidemiology, 2006